Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.34 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881834 | 0.84 | HTR3E (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL23270208 | 0.79 | AR (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL23270216 | 0.76 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL15563090 | 0.76 | CA1 (0.45) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL30543087 | 0.76 | CA1 (0.45) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL30543083 | 0.76 | CA1 (0.45) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL11287987 | 0.74 | HTR3E (0.40) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL456863 | 0.73 | MIF (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL23270205 | 0.71 | MAPT (0.54) | KMT2A | |
| SCHEMBL1040760 | 0.71 | CES2 (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290597-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | NEUROPORE THERAPIES, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210290597-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | NEUROPORE THERAPIES, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3810133-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | Neuropore Therapies, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-112512523-A | Methods of treating conditions associated with neurodegenerative disorders using inhibitors of OAT3 | 神经孔疗法股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290597-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | OAT, CLN6, SLC2A3 | HTR3E 738/4885HTR3B 552/4885HTR3A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.